Huntington's Disease (HD) is relatively uncommon, affecting approximately 1 in 10,000 individuals of European origin. The disease is caused by the expansion of a coding polymorphic CAG trinucleotide repeat located in exon 1 of the Huntingtin (HTT) gene
OMIM # 613004. The biological functions of HTT, and the pathogenic mechanism mediated by the mutant allele are not yet fully understood. There is no therapy in clinical use that can prevent or delay the onset of HD.
There have been many animal models of HD made to enable the investigation of the disease process, and also for use in pre-clinical pharmacological testing. A collaborative project between The University of Auckland, Harvard Medical School and the South Australian Research and Development Institute, resulted in the production first large mammalian model of HD - a transgenic sheep line termed OVT73. The OVT73 sheep line carries copies of full length human huntingtin cDNA with an expanded polyglutamine coding repeat of 73 units. The repeat is relatively stable on transmission with an expression level of approximately half an allele. Sheep have many advantages for neurological study and drug testing due to their large size, long lifespan, and complex brain structure which is comparable to humans. The transgenic sheep show no overt neurological symptoms (some >10 years of age), but do develop some of the hallmark brain pathology of HD such as huntingtin positive inclusions and altered expression of genes that are implicated in HD. The sheep have a measurable circadian abnormality, which is a characteristic behaviour of HD patients and a metabolic disruption. There are approximately one thousand OVT73 and control sheep available for research on the farm which is a normal pasture-based environment. Results from a wide range of OVT73 studies suggest that the model recapitulates the prodromal phase of Huntington's disease before motor age of onset.
A large series of data has been generated from a single cohort of OVT73 animals (n=6) and control sheep (n=6) killed at 5 years of age. This includes transcriptomic, proteomic and metabolic data collected from multiple tissue samples through various independent experimental analyses. This data has been collated and integrated into a single multidimensional platform presented on this website. The aim is to facilitate the 'multi-omic' exploration of the data for correlations and provides a more holistic view of the OVT73 sheep compared to controls.
Our aim is to share the OVT73 data with the HD research community, through an interactive database that can be queried for specific genes/proteins/metabolites of interest. The data can be explored using a range of statistical techniques and multivariate methods (presented as separate tabs at the top of the page). Alternatively, the raw datasets can be downloaded for further analyses here. The ultimate goal of this database is to offer another layer of HD data, from sheep, in an attempt to discover the causative mechanisms behind HD progression and identify potential therapeutic targets.
This interactive, web-based application allows the investigation and exploration of 'multi-omic' variables expressed in a sheep model of Huntington's disease (HD), termed OVT73. OVT73, which has been extensively characterised, represents a prodromal form of Huntington's disease (HD). The aim of this application is to share OVT73 data with the wider HD research community; allow variables of interest to be queried in a HD sheep model; bridge the gap between mouse and human HD studies and act as a hypothesis generator for HD mechanisms of pathogenesis.
If you would like to contact the Snell lab group or provide feedback, please use the Contact Us panel. If you would like to remain anonymous, please leave the name fields blank. This is an early stage project and any feedback provided will be greatly appreciated.
We would like to thank The University of Auckland for providing the services necessary for hosting and maintaining the application and providing the means to undertake the research that has been conducted.
We would also like to thank our current and previous collaborators for the opportunity to conduct experiments and allow the publication of resulting data.
The development of this application was funded by Brain Research New Zealand (BRNZ).
Created by Matthew Grant and Emily Mears, from the Snell lab group, at The University of Auckland.